Summary
The current spreading novel coronavirus SARS-CoV-2 is highly infectious and pathogenic. In this study, we screened the gene expression of three SARS-CoV-2 host receptors (ACE2, DC-SIGN and L-SIGN) and DC status in bulk and single cell transcriptomic datasets of upper airway, lung or blood of smokers, non-smokers and COVID-19 patients. We found smoking increased DC-SIGN gene expression and inhibited DC maturation and its ability of T cell stimulation. In COVID-19, DC-SIGN gene expression was interestingly decreased in lung DCs but increased in blood DCs. Strikingly, DCs shifted from cDCs to pDCs in COVID-19, but the shift was trapped in an immature stage (CD22+ or ANXA1+ DC) with MHCII downregulation in severe cases. This observation indicates that DCs in severe cases stimulate innate immune responses but fail to specifically recognize SARS-CoV-2. Our study provides insights into smoking effect on COVID-19 risk and the profound modulation of DC function in severe COVID-19.
Highlights Smoking upregulates the expression of ACE2 and CD209 and inhibits DC maturation in lungs. SARS-CoV-2 modulates the DCs proportion and CD209 expression differently in lung and blood.
Severe infection is characterized by DCs less capable of maturation, antigen presentation and MHCII expression.
DCs shift from cDCs to pDCs with SARS-CoV-2 infection but are trapped in an immature stage in severe cases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is supported by UofSC COVID-19 Initiative awarded to G.C.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the data were de-identified and study approval has been stated in original studies. The MEARDS study was reviewed and approved by institutional review boards of Massachusetts General Hospital (MGH) and Harvard School of Public Health (project approval number: 1999P0086071/MGH).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data derived from MEARDS was accessible upon request to Dr. David C. Christiani (dchris{at}hsph.harvard.edu) Data from other studies were openly available to the public without registration or application for access. Processed single cell transcriptomics data were available for visualization and exploration in SCANNER (https://www.thecailab.com/scanner/). The hosted data include three datasets from the normal airway samples from ever-smokers and non-smokers, as well as four datasets from the DCs of nasopharynx/pharynx, BULF and PBMC samples from COVID-19 patients and healthy people.
